CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis

被引:33
作者
Lai, Qiuhua [1 ]
Li, Qingyuan [1 ]
He, Chengcheng [1 ]
Fang, Yuxin [1 ]
Lin, Simin [1 ]
Cai, Jianqun [1 ]
Ding, Jian [1 ]
Zhong, Qian [1 ]
Zhang, Yue [1 ]
Wu, Changjie [1 ]
Wang, Xinke [1 ]
He, Juan [1 ]
Liu, Yongfeng [1 ]
Yan, Qun [1 ]
Li, Aimin [1 ]
Liu, Side [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou, Guangdong, Peoples R China
来源
AGING-US | 2020年 / 12卷 / 16期
关键词
colorectal cancer; CTCF; Hedgehog; P53; chemotherapy resistance; GENE-EXPRESSION; COLON-CANCER; PATHWAY; BINDING; SURVEILLANCE; INACTIVATION; BEVACIZUMAB; METASTASIS; CHROMATIN; THERAPY;
D O I
10.18632/aging.103648
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
CTCF is overexpressed in several cancers and plays crucial roles in regulating aggressiveness, but little is known about whether CTCF drives colorectal cancer progression. Here, we identified a tumor-promoting role for CTCF in colorectal cancer. Our study demonstrated that CTCF was upregulated in colorectal cancer specimens compared with adjacent noncancerous colorectal tissues. The overexpression of CTCF promoted colorectal cancer cell proliferation and tumor growth, while the opposite effects were observed in CTCF knockdown cells. Increased GLI1, Shh, PTCH1, and PTCH2 levels were observed in CTCF-overexpressing cells using western blot analyses. CCK-8 and apoptosis assays revealed that 5-fluorouracil chemosensitivity was negatively associated with CTCF expression. Furthermore, we identified that P53 is a direct transcriptional target gene of CTCF in colorectal cancer. Western blot and nuclear extract assays showed that inhibition of P53 can counteract Hedgehog signaling pathway repression induced by CTCF knockdown. In conclusion, we uncovered a crucial role for CTCF regulation that possibly involves the P53-Hedgehog axis and highlighted the clinical utility of colorectal cancer-specific potential therapeutic target as disease progression or clinical response biomarkers.yy
引用
收藏
页码:16270 / 16293
页数:24
相关论文
共 52 条
[1]   Adjuvant therapy for colon cancer - The pace quickens [J].
Allegra, C ;
Sargent, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26) :2746-2748
[2]   Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner [J].
Amantini, Consuelo ;
Morelli, Maria Beatrice ;
Nabissi, Massimo ;
Cardinali, Claudio ;
Santoni, Matteo ;
Gismondi, Angela ;
Santoni, Giorgio .
ONCOTARGET, 2016, 7 (31) :50180-50194
[3]   Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus [J].
Batlle-Lopez, A. ;
Cortiguera, M. G. ;
Rosa-Garrido, M. ;
Blanco, R. ;
del Cerro, E. ;
Torrano, V. ;
Wagner, S. D. ;
Delgado, M. D. .
ONCOGENE, 2015, 34 (02) :246-256
[4]   The protein CTCF is required for the enhancer blocking activity of vertebrate insulators [J].
Bell, AC ;
West, AG ;
Felsenfeld, G .
CELL, 1999, 98 (03) :387-396
[5]   Colorectal cancer [J].
Brenner, Hermann ;
Kloor, Matthias ;
Pox, Christian Peter .
LANCET, 2014, 383 (9927) :1490-1502
[6]   Dynamic changes of Sonic Hedgehog signaling pathway in gastric mucosa of rats with MNNG-induced gastric precancerous lesions [J].
Cai, Danli ;
Yu, Jianshun ;
Qiu, Jing ;
He, Beihui ;
Chen, Zhiyun ;
Yan, Maoxiang ;
Liu, Qingsheng .
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (07) :10827-10834
[7]   1,25-Dihydroxyvitamin D3 Inhibits the Differentiation and Migration of TH17 Cells to Protect against Experimental Autoimmune Encephalomyelitis [J].
Chang, Jae-Hoon ;
Cha, Hye-Ran ;
Lee, Dong-Sup ;
Seo, Kyoung Yul ;
Kweon, Mi-Na .
PLOS ONE, 2010, 5 (09)
[8]   CTCF, a candidate trans-acting factor for X-inactivation choice [J].
Chao, W ;
Huynh, KD ;
Spencer, RJ ;
Davidow, LS ;
Lee, JT .
SCIENCE, 2002, 295 (5553) :345-347
[9]   A PTCH1 Homolog Transcriptionally Activated by p53 Suppresses Hedgehog Signaling [J].
Chung, Jon H. ;
Larsen, Andrew R. ;
Chen, Evan ;
Bunz, Fred .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (47) :33020-33031
[10]   FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study [J].
Cremolini, Chiara ;
Loupakis, Fotios ;
Antoniotti, Carlotta ;
Lupi, Cristiana ;
Sensi, Elisa ;
Lonardi, Sara ;
Mezi, Silvia ;
Tomasello, Gianluca ;
Ronzoni, Monica ;
Zaniboni, Alberto ;
Tonini, Giuseppe ;
Carlomagno, Chiara ;
Allegrini, Giacomo ;
Chiara, Silvana ;
D'Amico, Mauro ;
Granetto, Cristina ;
Cazzaniga, Marina ;
Boni, Luca ;
Fontanini, Gabriella ;
Falcone, Alfredo .
LANCET ONCOLOGY, 2015, 16 (13) :1306-1315